
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$6.31
+US$0.36 · +6.05%
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
前收盘价
US$6.31
+US$0.36 · +6.05%
盘前
US$6.01
−US$0.30 · -4.75%
10月12日 7:12 ET
盘中时间采用ET。市场数据可能有所延迟。
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
日内区间
当前US$6.31
52周区间
当前US$6.31
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
81
深度低估
情绪
49
多空交织
风险
58
风险偏高
动量
49
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
日内区间
当前US$6.31
52周区间
当前US$6.31
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6185.8万 USD | 5613.4万 USD | 7918.1万 USD | 7366.9万 USD | 6313.4万 USD |
| 销货成本 | 2518.2万 USD | 2087.9万 USD | 2666万 USD | 3077.5万 USD | 3208.4万 USD |
| 毛利 | 3667.6万 USD | 3525.5万 USD | 5252.1万 USD | 4289.4万 USD | 3105万 USD |
| 研究与开发 | 48万 USD | 985.7万 USD | 754.1万 USD | 1094.3万 USD | 1655.8万 USD |
| 销售、一般及管理费用 | 4436.8万 USD | 4020.4万 USD | 4391万 USD | 5946.8万 USD | 3983.3万 USD |
| 营业费用 | 4484.8万 USD | 4893.2万 USD | 5459.4万 USD | 7041.1万 USD | 6593.1万 USD |
| 利息收入 | 58.9万 USD | 75.7万 USD | 32.2万 USD | 6万 USD | 2000 USD |
| 利息支出 | 369.8万 USD | 270万 USD | 169.8万 USD | 201.9万 USD | 703.4万 USD |
| 折旧和摊销 | 434.6万 USD | 351.5万 USD | 385.5万 USD | 436.5万 USD | 256万 USD |
| 营业利润 | −817.2万 USD | −1367.7万 USD | −207.3万 USD | −2751.7万 USD | −3488.1万 USD |
| 净利润 | −1143.1万 USD | −1467.2万 USD | −385.3万 USD | −2962.8万 USD | −4399.4万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI348.59万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF138.54万0.00%954亿 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC26.33万0.02%13.17亿 USD0.60%US$183+0.11%
Invesco NASDAQ Future Gen 200 ETFQQQS10.21万0.45%2275.83万 USD0.20%US$42.145+1.39%
U.S. Micro Cap Portfolio ETFDFMC4万0.00%75.58亿 USD0.43%US$57.813+0.20%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.69万0.00%455.91亿 USD0.17%US$84.44+0.44%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Invesco NASDAQ Future Gen 200 ETFQQQS
U.S. Micro Cap Portfolio ETFDFMC
U.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。